Marta Moreno-Torres

Mrs. Marta Moreno-Torres

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Cell Metabolism
Verified
Journal Article
Open access
ESElahu G. Sustarsic
Elahu G. Sustarsic
TMTao Ma
Tao Ma
MLMatthew D. Lynes
Matthew D. Lynes
MLMichael Larsen
Michael Larsen
IKIuliia Karavaeva
Iuliia Karavaeva
ZGZachary Gerhart-Hines
Zachary Gerhart-Hines
Activation of energy expenditure in thermogenic fat is a promising strategy to improve metabolic health, yet the dynamic processes that evoke this response are poorly understood. Here we show that synthesis of the mitochondrial phospholipid cardiolipin is indispensable for stimulating and sustaining thermogenic fat function. Cardiolipin biosynthesis is robustly induced in brown and beige adipose upon cold exposure. Mimicking this response through overexpression of cardiolipin synthase (Crls1) enhances energy consumption in mouse and human adipocytes. Crls1 deficiency in thermogenic adipocytes diminishes inducible mitochondrial uncoupling and elicits a nuclear transcriptional response through endoplasmic reticulum stress-mediated retrograde communication. Cardiolipin depletion in brown and beige fat abolishes adipose thermogenesis and glucose uptake, which renders animals insulin resistant. We further identify a rare human CRLS1 variant associated with insulin resistance and show that adipose CRLS1 levels positively correlate with insulin sensitivity. Thus, adipose cardiolipin has a powerful impact on organismal energy homeostasis through thermogenic fat bioenergetics.

20 September 2012 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
AAAlessandro Agostini
Alessandro Agostini
LMLaura Mondragón Martínez
Laura Mondragón Martínez
Andrea BernardosAndrea Bernardos
Andrea Bernardos
RMRamón Martínez-Máñez
Ramón Martínez-Máñez
MMM. Dolores Marcos
M. Dolores Marcos
JMJosé Ramón Murguía
José Ramón Murguía

10 September 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
Marta Moreno-TorresMarta Moreno-Torres
Marta Moreno-Torres
MJMalika Jaquenoud
Malika Jaquenoud
CVClaudio De Virgilio
Claudio De Virgilio
The target of rapamycin complex 1 (TORC1) pathway couples nutrient, energy and hormonal signals with eukaryotic cell growth and division. In yeast, TORC1 coordinates growth with G 1 –S cell cycle progression, also coined as START, by favouring the expression of G 1 cyclins that activate cyclin-dependent protein kinases (CDKs) and by destabilizing the CDK inhibitor Sic1. Following TORC1 downregulation by rapamycin treatment or nutrient limitation, clearance of G 1 cyclins and C-terminal phosphorylation of Sic1 by unknown protein kinases are both required for Sic1 to escape ubiquitin-dependent proteolysis prompted by its flagging via the SCF Cdc4 (Skp1/Cul1/F-box protein) ubiquitin ligase complex. Here we show that the stabilizing phosphorylation event within the C-terminus of Sic1 requires stimulation of the mitogen-activated protein kinase, Mpk1, and inhibition of the Cdc55 protein phosphatase 2A (PP2A Cdc55 ) by greatwall kinase-activated endosulfines. Thus, Mpk1 and the greatwall kinase pathway serve TORC1 to coordinate the phosphorylation status of Sic1 and consequently START with nutrient availability.

19 June 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
Marta Moreno-TorresMarta Moreno-Torres
Marta Moreno-Torres
Guillermo QuintásGuillermo Quintás
Guillermo Quintás
José CastellJosé Castell
José Castell
Drug-induced liver injury (DILI) is one of the most frequent adverse clinical reactions and a relevant cause of morbidity and mortality. Hepatotoxicity is among the major reasons for drug withdrawal during post-market and late development stages, representing a major concern to the pharmaceutical industry. The current biochemical parameters for the detection of DILI are based on enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), alkaline phosphatase (ALP)) and bilirubin serum levels that are not specific of DILI and therefore there is an increasing interest on novel, specific, DILI biomarkers discovery. Metabolomics has emerged as a tool with a great potential for biomarker discovery, especially in disease diagnosis, and assessment of drug toxicity or efficacy. This review summarizes the multistep approaches in DILI biomarker research and discovery based on metabolomics and the principal outcomes from the research performed in this field. For that purpose, we have reviewed the recent scientific literature from PubMed, Web of Science, EMBASE, and PubTator using the terms “metabolomics”, “DILI”, and “humans”. Despite the undoubted contribution of metabolomics to our understanding of the underlying mechanisms of DILI and the identification of promising novel metabolite biomarkers, there are still some inconsistencies and limitations that hinder the translation of these research findings into general clinical practice, probably due to the variability of the methods used as well to the different mechanisms elicited by the DILI causing agent.

2 May 2017 in Cell Discovery
Verified
Journal Article
Open access
PDF file
Marta Moreno-TorresMarta Moreno-Torres
Marta Moreno-Torres
MJMalika Jaquenoud
Malika Jaquenoud
MPMarie-Pierre Péli-Gulli
Marie-Pierre Péli-Gulli
RNRaffaele Nicastro
Raffaele Nicastro
CVClaudio De Virgilio
Claudio De Virgilio
Eukaryotic cell cycle progression through G1–S is driven by hormonal and growth-related signals that are transmitted by the target of rapamycin complex 1 (TORC1) pathway. In yeast, inactivation of TORC1 restricts G1–S transition due to the rapid clearance of G1 cyclins (Cln) and the stabilization of the B-type cyclin (Clb) cyclin-dependent kinase (CDK) inhibitor Sic1. The latter mechanism remains mysterious but requires the phosphorylation of Sic1-Thr173 by Mpk1 and inactivation of the Sic1-pThr173-targeting phosphatase (PP2ACdc55) through greatwall kinase-activated endosulfines. Here we show that the Sic1-pThr173 residue serves as a specific docking site for the CDK phospho-acceptor subunit Cks1 that sequesters, together with a C-terminal Clb5-binding motif in Sic1, Clb5-CDK-Cks1 complexes, thereby preventing them from flagging Sic1 for ubiquitin-dependent proteolysis. Interestingly, this functional switch of Sic1 from a target to an inhibitor of cyclin-CDK-Cks1 also operates in proliferating cells and is coordinated by the greatwall kinase, which responds to both Cln-CDK-dependent cell-cycle and TORC1-mediated nutritional cues.

26 March 2020 in Metabolites
Verified
Journal Article
Open access
PDF file
ITIsabel Ten-Doménech
Isabel Ten-Doménech
TMTeresa Martínez-Sena
Teresa Martínez-Sena
Marta Moreno-TorresMarta Moreno-Torres
Marta Moreno-Torres
JSJuan Daniel Sanjuan-Herráez
Juan Daniel Sanjuan-Herráez
José CastellJosé Castell
José Castell
Julia KuligowskiJulia Kuligowski
Julia Kuligowski
One of the most widely used strategies for metabolite annotation in untargeted LCMS is based on the analysis of MSn spectra acquired using data-dependent acquisition (DDA), where precursor ions are sequentially selected from MS scans based on user-selected criteria. However, the number of MSn spectra that can be acquired during a chromatogram is limited and a trade-off between analytical speed, sensitivity and coverage must be ensured. In this research, we compare four different strategies for automated MS2 DDA, which can be easily implemented in the frame of standard QA/QC workflows for untargeted LC–MS. These strategies consist of (i) DDA in the MS working range; (ii) iterated DDA split into several m/z intervals; (iii) dynamic iterated DDA of (pre)selected potentially informative features; and (iv) dynamic iterated DDA of (pre)annotated metabolic features using a reference database. Their performance was assessed using the analysis of human milk samples as model example by comparing the percentage of LC–MS features selected as the precursor ion for MS2, the number, and class of annotated features, the speed and confidence of feature annotation, and the number of LC runs required.